Loading...
Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report
PURPOSE: HER2 mutations are identified in approximately 2% of non-small-cell lung cancer (NSCLC) cases; however, until now, there are no approved standard targeted therapy for NSCLC patients harboring HER2 mutations. CASE PRESENTATION: We present a 63-year-old male with a long smoking history, who w...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913761/ https://ncbi.nlm.nih.gov/pubmed/31849493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S228726 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|